Chemours CC Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 15.1%-0.4pp | 15.5%-1.8pp | 17.3%-0.9pp | 18.2%-0.7pp | 18.9%-0.8pp | |
| Net margin | -7%-0.4pp | -6.6%-0.7pp | -6%+1.3pp | -7.3%-7.5pp | 0.2%-1.0pp | |
| Returns | ||||||
| Return on equity | -105%-11.0pp | -94%-17.7pp | -76.3%+14.5pp | -90.9%-92.7pp | 1.8%-9.2pp | |
| Return on invested capital | -0.6%-0.4pp | -0.2%-1.6pp | 1.4%+1.6pp | -0.3%-3.7pp | 3.4%-2.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.8×0.0× | 1.8×+0.1× | 1.7×0.0× | 1.7×-0.1× | 1.8×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 20.6×+2.9× | 17.7×+1.5× | 16.2×-3.3× | 19.5×+11.7× | 7.8×+0.1× | |
| Net debt / EBITDA | 12.7×+1.4× | 11.3×+1.5× | 9.8×-2.7× | 12.5×+6.1× | 6.4×+0.9× | |
| Valuation | ||||||
| Market capitalization | $3.31B+87.1% | $1.77B-25.5% | $2.37B+42.1% | $1.67B-17.5% | $2.02B-19.9% | |
| Price / sales | 0.6×+0.3× | 0.3×-0.1× | 0.4×+0.1× | 0.3×-0.1× | 0.3×-0.1× | |
| Price / book | 15.4×+8.3× | 7.1×-1.6× | 8.7×+1.3× | 7.3×+3.7× | 3.6×-0.8× | |
| EV / EBITDA | 23.6×+6.9× | 16.7×+0.8× | 15.8×-2.0× | 17.8×+8.1× | 9.7×+0.4× | |
| Dividend yield | 1.6%-2.8pp | 4.4%+0.2pp | 4.2%-3.3pp | 7.4%+0.1pp | 7.3%+1.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Chemours's ratios come from?
- Every ratio is computed from Chemours's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.